Product logo
  • Home
  • Sign Up
Product logo

Nippon India Nifty Pharma ETF

News

Switch to
More ontickertape logoapp
    Home
    Sign Up

    Nippon India Nifty Pharma ETF

    PHARMABEESETF
    12.600.02 (+0.16%)

    Tracking NIFTY PHARMA - TRI

    Investment Checklist

    NAV
    The net asset value (NAV) of an ETF is based on the current prices of the stocks/assets in the fund and an actual accounting of the total cash in the fund at the time of calculation. Market price can be different from real time NAV due to late market activity and both tend to converge periodically. A market price close to real time NAV is much better for investment!

    Insufficient Data

    Expense Ratio
    ETFs charge their shareholders an expense ratio to cover the fund’s operating expenses, which is expressed as a percentage of the fund’s average net assets. This directly reduces the fund’s returns to its shareholders, and, therefore, the value of the investment. Lower is always better!

    Less expense ratio implies better returns over the long term

    Tracking Error
    Tracking error is the difference between the performance of the ETF and that of the underlying benchmark it's tracking. It's an important metric for investors who want to replicate an index's performance by investing in the ETF. The lower the tracking error, the better is the ETF's performance aligned with the investor's expectations

    ETF has been able to closely match its benchmark's returns

    Return vs FD Rates
    Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If the ETFs price return is lower than this rate, investors are better off investing the amount in a FD

    Insufficient Data

    Entry Point
    High demand for an ETF increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the ETF

    Good time to consider, as ETF is not in overbought zone

    Get your Zerodha accountOpen Now
    OverviewPeersNewsEvents
    129

    News & Opinions

    129
    Articles & Videos
    News Thumbnail
    Latest

    Track Record: Why Nifty may cheer investors after Budget

    5 hours ago•Economic Times

    News Thumbnail
    Latest

    Market may remain in a sell-on-rally mode till Nifty stays below 17,850: Rupak De

    5 hours ago•Economic Times

    News Thumbnail
    Latest

    More than 50 smallcaps fall 10-26% in this week’s market carnage

    5 hours ago•Moneycontrol

    News Thumbnail
    News Video

    After The Sharp Correction, Will The Nifty Take Support At 200 DMA? | Editors' Roundtable

    19 hours ago•CNBC-TV18

    News Thumbnail

    Adani stock rout roils markets; Sensex falls 874 pts, Nifty ends at 17,600

    19 hours ago•Business Standard

    News Thumbnail
    News Video

    Stock Market Snapshot; Adani Under Pressure; Spotlight On Budget 2023 & More | India Business Hour

    19 hours ago•CNBC-TV18

    News Thumbnail

    Budget blues: Nifty set for worst run, falls 2.8% in past 3 sessions

    19 hours ago•Business Standard

    News Thumbnail
    News Video

    Union Budget 2023: An Explainer On Capital Expenditure And Revenue Expenditure

    20 hours ago•Zee Business

    News Thumbnail

    Sensex, Nifty drop over 1% after report on Adani group, FII caution

    23 hours ago•The Hindu Businessline

    News Thumbnail

    Bloodbath on D-Street continues as Sensex down by 1,200 pts, Nifty near 17,500

    23 hours ago•Livemint

    © Powered byTickertape.ViewPHARMABEESon 

    EmailHelpBlog

    NSE & BSE – SEBI Registration No: INZ000031633 | CDSL - SEBI  Registration No: IN-DP-431-2019

    Zerodha - NSE & BSE – SEBI Reg. No.: INZ000031633
    Zerodha - CDSL - SEBI Reg. No: IN-DP-431-2019